Owen Mumford and Stevanato Group sign Exclusive Collaboration Agreement for the Innovative Aidaptus Auto-injector
The Aidaptus disposable auto-injector platform, created by Owen Mumford, will be offered jointly to global biopharma companies, supporting their drug development with engineering and manufacturing assistance from Stevanato Group.
WOODSTOCK, England – May 4, 2022 — Owen Mumford Ltd, a global leader in the design, development, and manufacturing of injectable drug delivery systems for the pharmaceutical, biotech, and generics industries, has signed an exclusive agreement with Stevanato Group, a worldwide provider of drug containment, drug delivery, and diagnostic solutions, for the Aidaptus auto-injector.
This agreement makes Stevanato Group the exclusive manufacturing partner for the Owen Mumford-designed auto-injector, delivering a complete set of capabilities to its pharmaceutical customers. Stevanato Group will mold the components for Aidaptus and supply both final and sub-assembly equipment, in addition to offering leading prefilled syringes to give pharmaceutical clients the ability to create finished products for patients. Both Stevanato Group at its global manufacturing facilities and Owen Mumford at its automated assembly center of excellence in the UK will handle assembly of the components.
The partnership is meant to bring added value for customers, combining world-class device expertise with top-tier manufacturing capabilities. It’s expected to make device production more efficient and maximize the innovative value of the Aidaptus platform for the market.
Aidaptus is a single-use, 2-step auto-injector with a flexible design that fits both 1mL and 2.25mL prefilled glass syringes in the same core device. It also includes plunger sensing technology with a self-adjusting plunger rod that automatically adapts to individual plunger positions and different fill volumes in each syringe, no part changes needed. The auto-injector can also handle a unique range of drug viscosities.
With more than 70 years of experience, Owen Mumford designs and produces innovative medical devices aimed at meeting the needs of both pharmaceutical companies and their patients by making products easy to use, improving safety, and increasing patient compliance. The company focuses on designing devices that reduce complexity and risk for pharmaceutical and biotech companies when creating combination products.
“Aidaptus will help patients self-administer their treatments using a device that’s simple and easy to use,” said Adam Mumford, Director of Owen Mumford. “At the same time, this auto-injector can help reduce complexity, minimize supply chain risk, and simplify final assembly for pharmaceutical and biotech companies because it adapts to different viscosities, syringe sizes, and fill volumes. Changes to these aspects often occur during the development or lifecycle management of injectable drug products. Now for the first time, the device itself does not need to change as well.”
Mauro Stocchi, Chief Business Officer of Stevanato Group, commented: “We believe this agreement is a key step in boosting and expanding opportunities in our drug delivery systems portfolio as we broaden our capabilities in this important market. As we constantly collaborate with our customers to meet their needs, we continue to see growing demand for auto-injectors. Through this agreement, we’ll take full advantage of Stevanato Group’s integrated abilities by providing device manufacturing, assembly equipment, along with pre-fillable syringes and inspection systems.”
“Stevanato Group is a well-established company with an excellent standing in the pharmaceutical industry,” said Michael Earl, Director of Pharmaceutical Services at Owen Mumford. “It has deep experience in molding and assembly processes and will reliably supply high-quality components for our Aidaptus auto-injector. Collaborating with Stevanato Group will help us reach more customers so they can benefit from the advantages of this cutting-edge new platform.”
Steven Kaufman, VP for Drug Delivery Systems at Stevanato Group, added: “The Aidaptus auto-injector platform blends patient-friendly use with quicker time-to-market for pharmaceutical organizations. We want to be the strategic partner for developing innovative combination products as we keep growing our integrated capabilities in drug delivery, and for this reason, we are very excited to work with Owen Mumford and help introduce this exciting new auto-injector platform.”
The collaboration will be formally introduced at Pharmapack 2022. Owen Mumford will proudly present Aidaptus on May 18 and 19 at Pharmapack Europe, Paris Expo, booth no. C52.